Test Price
1,800 AED✅ Home Collection Available
HLA Mixed Antibody Screen – PRA Class I, II & MICA Test in UAE | 1800 AED
Executive Summary & Core Metrics
🔬 Clinical Snapshot: High-resolution Luminex X-Map assay detecting circulating anti-HLA (Class I & II) and MICA antibodies in transplant candidates or recipients. This solid-phase immunoassay delivers 99.9% diagnostic sensitivity for immunologic risk stratification.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The HLA Mixed Antibody Screen – PRA Class I, II & MICA test detects circulating anti-HLA and MICA antibodies in transplant candidates or recipients using Luminex X-Map technology. This high-resolution assay identifies immunologic sensitization to guide organ allocation and immunosuppressive therapy. A single serum specimen is processed against a comprehensive bead panel that covers HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, -DPB1, and MICA alleles, providing a complete anti-HLA antibody profile including mean fluorescence intensity (MFI) values for each specificity.
| Feature | Our Test (DHA-Aligned) | Closest Alternative |
|---|---|---|
| Methodology | Luminex X-Map (single antigen beads) | Complement-Dependent Cytotoxicity (CDC) |
| Antibody Coverage | HLA Class I, II & MICA simultaneously | HLA Class I and II only (no MICA) |
| Turnaround Time | 10–12 business days | 7–14 days (often longer for CDC crossmatch) |
| Sample Requirement | 3 mL serum (1 SST); recipient sample only | May require donor lymphocytes in addition |
| Compliance | Federal Decree-Law No. 45 of 2021 (PDPL) & Federal Law No. 2 of 2019 on ICT in Health | Varies by provider |
Physician Insight & Safety Protocols
“A positive antibody screen is not a contraindication to transplantation—it is a precise immunologic map that guides tailored desensitization and donor selection. When combined with virtual crossmatching and a thorough clinical history, this assay empowers the transplant team to optimize outcomes even in highly sensitized candidates. Always correlate these results with your transplant nephrologist or hepatologist before making any therapeutic changes.” — Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
⚠️ Important Medication Advisory
Do not discontinue, adjust, or modify any prescribed immunosuppressive or antihypertensive medication without explicit direction from your treating physician. This laboratory test provides immunologic risk information and is not a standalone tool for clinical decision-making. Always consult your transplant team for personalized management.
🚨 Safety Exclusion Criteria & ER Red Flags
- Active febrile illness or systemic infection within 48 hours of collection may delay testing and alter antibody profiles.
- Recent blood transfusion (within 6 weeks) can introduce passive antibodies and interfere with donor-specific antibody interpretation.
- If you experience graft tenderness, sudden oliguria, fever, or dyspnea post-transplant, seek emergency care immediately—do not wait for test results.
- Collection is deferred for patients with acute hemodynamic instability or uncontrolled sepsis.
Patient FAQ & Clinical Guidance
1. What does a positive PRA Class I, II and MICA result mean for my transplant eligibility?
Quick Answer: A positive panel reactive antibody (PRA) result indicates the presence of antibodies against specific HLA or MICA antigens, which may elevate the risk of antibody-mediated rejection if unaddressed. However, modern desensitization protocols, paired kidney exchange programs, and virtual crossmatching enable successful transplantation in highly sensitized patients. Your transplant team will evaluate the MFI strength, antibody specificity, and donor availability to determine the safest path forward—a positive result alone does not disqualify you.
2. Why is only a recipient sample needed, and why must I provide a clinical history?
Quick Answer: The Luminex X-Map assay exclusively screens recipient serum for pre-formed antibodies; no donor cells are required for the antibody detection phase. A brief clinical history—including prior transplants, pregnancies, blood transfusions, and any history of autoimmune disease—is essential to correctly interpret antibody specificities and avoid misclassifying naturally occurring or passively acquired antibodies as donor-reactive.
3. How do I arrange home collection and verify direct insurance billing for the 1800 AED test?
Quick Answer: Contact our UAE-based support via WhatsApp at +971 54 548 8731 to schedule a VIP mobile phlebotomy visit between 8 AM and 11 PM; same-day appointments are often available. Provide your insurance policy details at the time of booking, and our team will verify direct billing eligibility within one hour, ensuring you pay only the applicable deductible (if any) at the time of service.
4. Can this test be done while I am on dialysis or after a previous transplant?
Quick Answer: Yes. The test is specifically designed for transplant candidates and recipients regardless of dialysis status or prior transplant history. However, blood should ideally be drawn before a dialysis session to avoid hemodilution, and any history of transplant or transfusion must be clearly documented on the requisition form for accurate interpretation of antibody specificities.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates under the framework of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient health information, including HLA antibody profiles and clinical metadata, is encrypted in transit and at rest, with access restricted to authorized clinical personnel only. Federal Decree-Law No. 4 of 2016 on Medical Liability governs the clinical safety and informed consent protocols applied throughout the pre- and post-test counseling process.
Clinical & Logistical Metadata
| Test Name | HLA Mixed Antibody Screen – PRA Class I, II & MICA |
| Price (AED) | 1,800 AED |
| Turnaround Time | 10–12 business days |
| Sample Type / Matrix | 3 mL serum (SST); peripheral whole blood |
| Methodology Used | Luminex X-Map single antigen bead array |
| ICD-10-CM Code | Z01.818 |
| LOINC Code | 48349-2 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians